A Phase I Dose Escalation Study of the Safety,Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Patients with Select Advanced Solid Tumors

Lessons Learned

• The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
• The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.

BackgroundThis phase I, open‐label study assessed ipilimumab safety, tolerability, pharmacokinetics (PK), immunogenicity, and antitumor activity in Chinese patients with unresectable, metastatic, recurrent malignant melanoma (MM) or nasopharyngeal carcinoma (NPC).MethodsOf 39 patients enrolled, 25 received ipilimumab (11 patients received 3 mg/kg, and 14 patients received 10 mg/kg). Reasons for not receiving treatment were withdrawal of consent (3 patients), no longer meeting the criteria (10 patients), and one recorded as “other.” During the induction phase, patients received ipilimumab (3 mg/kg, i.v.), on day 1 of a 3‐week cycle, to a maximum of four doses or progressive disease (PD). During the maintenance phase at week 24, patients received ipilimumab (3 mg/kg, i.v.) on day 1 of a 12‐week cycle, to a maximum of 3 years or PD. Considering the co‐primary safety and PK endpoints, the successive dosing required nine patients with two or fewer dose‐limiting toxicities during the 42‐day observation period to proceed with a new cohort of nine patients at 10 mg/kg.ResultsIpilimumab safety and PK profiles were similar in Chinese and predominantly White populations. Ipilimumab was well tolerated. Most adverse events (AEs) were grades 1–2 and experienced by 11 patients treated with 3 mg/kg and 14 patients treated with 10 mg/kg. There were no new safety concerns. Incidence of anti‐ipilimumab antibodies was low (1 of 10 in the 3 mg/kg patients and 2 of 13 in the 10 mg/kg patients) and without safety implications. In the 3 mg/kg group, 8 of 11 patients had PD. In the 10 mg/kg group (all NPC, 0 MM patients), 11 of 14 patients had PD. Three patients had stable disease (one at 3 mg/kg and two at 10 mg/kg).ConclusionIpilimumab was well tolerated in Chinese patients, showing similar safety and PK to previous studies in predominantly White populations.     

城市社区老年护理方案

概述了城市社区老年护理的需求及现状,并从建立社区健康卡,进行健康教育与咨询、心理护理,发挥社区医院、地段医院的作用,建立家庭护理单元等叙述了城市社区老年护理的措施,并展望了城市社区老年护理发展方向。     

The effect of 2,4-diamino-6-hydroxy-pyrimidine on postburn Staphylococcus aureus sepsis in rats

GTP-cyclohydrolase I (GTP-CHI) is the first and rate-limiting enzyme for the de novo biosynthesis of biopterin. The present study was to observe the effect of 2,4-diamino-6-hydroxy-pyrimidine (DAHP),an inhibtor of GTP-CHI, on the development of postburn Staphylococcus aureus sepsis. Methods: 56 male Wistar rats were randomly divided into four groups as follows: normal control group (n= 10), scald control group(n= 10),pos tburn sepsis group (n= 20) and DA HP treatment group (n= 16). In the scald control group, rats were subjected to a 20% total body surface area (TBSA) Ⅲ° scald injury, then sacrificed at 24 hrs. In the postburn sepsis group (n=20), rats were inflicted with 20% TBSA Ⅲ° scald followed by Staphylococcus aureus challenge, and they were further divided into 2 and 6 hrs groups. In the DAHP treatment group (n= 16), animals were intraperitoneally injected with a dose of 1g/kg DAHP prior to Staphylococcus aureus challenge, and then further divided into 2, 6 hrs groups. Tissue samples from liver, kidneys, lungs and heart were collected to determine GTP-CHI, inducible nitric oxide synthase (iNOS) and tumor necrosis factor-α (TNF-α) mRNA expression. Meanwhile, biopterin and nitric oxide (NO) levels in these tissues were also measured. Results: After the scald injury followed by Staphylococcus aureus challenge, GTP-CHI mRNA expression and biopterin levels significantly elevated in various tissues such as liver, heart, kidneys and lungs, so did the values of iNOS mRNA expression and NO formation (P＜0.01). Pretreatment with DAHP could significantly reduce GTP-CHI/biopterin induction (P＜0. 05～0. 01), and the up-regulation of iNOS/NO was also suppressed. Furthermore, DAHP administration could also inhibit the gene expression of TNF-α. 2 hrs after septic challenge, TNF-α mRNA expression in liver, kidneys and lungs in DAHP-treated group were 35.7%, 37.3% and 33.0% of those in postburn septic group, respectively. Additionally, in animals without DAHP treatment, the 6-hour mortality was 55.6% (20/36), while it was only 25.0% in DAHP-treated animals (4/16, P=0. 08). Conclusions: Early treatment with DAHP might be a potential strategy to prevent the development of postburn Staphylococcal sepsis, which appears to be associated with down-regulation of biopterin and NO formation by DAHP.     

富氧水防治急性高原病的效果观察

目的:观察饮用富氧水防治急性高原病的效果。方法:36名受试者自海拔1400m驻地乘汽车2天到达海拔3700m当日随机分两组,实验组(18人)口服5%葡萄糖注射液制成的富氧水,对照组(18人)口服5%葡萄糖注射液,均每次500mL,一日2次,直至进入海拔5200m某哨卡第6天,共服液8天。以军用卫生标准GJB1098-91"急性高原反应的诊断和处理原则"随访记录受试者进入哨卡第2天、4天、6天急性高原反应症状,然后分度与评分。同时检测血氧饱和度(SaO2)和脉率。结果:进驻哨卡第2天和第4天实验组较对照组急性高原反应分值减少,而SaO2增高(P<0.05或P<0.01),进驻哨卡第2天实验组较对照组脉率降低(P<0.05)。结论:饮用富氧水有防治急性高原病的效果。     

激活Wnt/β-catenin通路促进肝癌细胞上皮间充质转化

探讨丝氨酸精氨酸蛋白激酶1（SRPK1）对肝癌细胞株HepG2上皮间充质转化（EMT）的作用。方法 通过Ualcan及TIMER 2.0数据库分析SRPK1 mRNA在肝细胞癌（LIHC）与正常样本、配对癌旁样本之间的表达差异,与生存时间、临床分期、病理分期、TP53变异、人种、性别、年龄、体重等临床资料的关系。用HPA数据库的免疫组化数据验证SRPK1蛋白在LIHC组织及正常对照间的表达差异。构建SRPK1过表达及抑表达的HepG2细胞,并根据SRPK1表达差异分为SRPK1组及对照的Vector组,shRNA组及对照的Scramble组。Western blot检测4组细胞株SRPK1的蛋白水平。Western Blot、免疫荧光检测EMT分子标记物E-cadherin、Vimentin蛋白表达差异。核浆蛋白分离比较细胞β-catenin入核程度的变化。GEPIA2数据库分析在LIHC组织中SRPK1与Wnt/β-catenin通路下游基因Twist、MYC、MMP9的相关性,Real-time PCR验证SRPK1对Twist、MYC、MMP 9表达的影响。结果 SRPK1表达在LIHC组织中表达显著高于正常对照及配对癌旁样本（P＜0.05）,随疾病分期及病理分级增加而增加（P＜0.05）,高表达SRPK1组总生存期低于低表达组（P=0.035）,LIHC患者TP53突变组SRPK1表达高于非突变组（P＜0.05）,在不同种族、性别、年龄、体重间无差别（P＞0.05）。SRPK1过表达HepG2细胞E-cadherin表达下降,Vimentin表达增加（P＜0.05）;抑表达细胞E-cadherin增加,Vimentin下降（P＜0.05）。SRPK1在LIHC组织中分别与Twist、MYC、MMP9表达呈正相关性（P＜0.05）;SRPK1过表达细胞β-catenin蛋白在细胞核中表达增加（P＜0.05）,Twist、MYC、MMP9表达增加（P＜0.05）;反之,抑表达细胞β-catenin在细胞核中表达下降（P＜0.05）,Twist、MYC、MMP9表达减少（P＜0.05）。结论 SRPK1可能通过Wnt/β-catenin通路促进HepG2细胞EMT活化     

脉络宁高压氧治疗突发性聋

目的：观察脉络宁高压氧治疗突发性聋的疗效。方法：应用脉络宁20ml加入5％葡萄糖注射液或氯化钠注射液250ml中滴注,每日1次,连续使用1月,同时接受高压氧治疗,每日1次,10次为1疗程;并与西医治疗组进行对照。结果：脉络宁高压氧治疗突发性聋总有效率85．72％,显著高于西医治疗组有效率的54．10％;脉络宁高压氧治疗突发性聋的疗效与治疗时间的早晚有关,治疗愈早,疗效愈好,疗程与疗效无显著的相关性。结论：脉络宁高压氧治疗突发性聋,听力恢复快,无副作用,优于单纯西医治疗。     

基于慢性乙型病毒性肝炎诊断路径的实验诊断学教学模式初探

探讨建立涵盖慢性乙型病毒性肝炎(CHB)诊断与鉴别诊断、治疗、药物选择及毒副作用预测、疗效监测、预后评估等全过程的疾病临床检验诊断路径的教学模式。根据CHB临床诊疗指南, 制订与疾病不同阶段相关的实验室检查检测策略, 建立CHB临床检验诊断路径, 以武汉大学第一临床学院2016级和2017级八年制本科生为研究对象, 通过随堂问卷比较其课堂教学效果。本研究首先建立了获得临床医生认可的CHB临床检验诊断路径, 其涵盖CHB疾病的诊断与鉴别诊断、治疗、药物选择及毒副作用预测、疗效监测、预后评估等全过程。该路径应用于2017级临床医学本科生课堂教学后, 教学质量评估指标均有较大程度的提升。此外, 随堂测验得分也有显著提高。综上, 基于CHB临床检验诊断路径的实验诊断学教学模式, 实现了实验诊断学与临床医学的融合, 提升了学生对CHB诊疗中各种实验室检查检测的整体认识, 教学质量得到了提高。     

复合蛋白锌的基础研究与临床应用研究

给昆明小鼠服用复合蛋白锌（以下简称ＣＰＺ）,低剂量组０．４６８ｇ／ｋｇ,高剂量组４．６８ｇ／ｋｇ,观察结果表明：ＣＰＺ能使小鼠胃肠推进性蠕动加强;给Ｗｉｓｔａｒ大鼠服用ＣＰＺ,低剂量为０．３２４ｇ／ｋｇ,高剂量为３．２４／ｋｇ,观察结果表明,ＣＰＺ能使大鼠的胃蛋白酶活性明显增强,与对照组比较差异显著。并观察了ＣＰＺ治疗小儿偏食厌食的效果